Galena Biopharma proposes public offering of common shares and warrants.
M2 EQUITYBITES-December 18, 2012-Galena Biopharma proposes public offering of common shares and warrants(C)2012 M2 COMMUNICATIONS http://www.m2.com
Biopharmaceutical company Galena Biopharma (NasdaqCM :GALE) said on Monday that it plans to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.
Net proceeds from the offering are expected to be used by the company to conduct its ongoing Phase 3 clinical trial for NeuVax, its Phase 1/2 clinical trial for Folate Binding Protein-E39 (FBP), the planned Phase 2 clinical trial for NeuVax in combination with trastuzumab (Herceptin) and for general corporate purposes.
Subject to market and other conditions, there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Piper Jaffray & Co is acting as the sole book-running manager for the offering.
((Comments on this story may be sent to email@example.com)).END.PUB430>PDDecember 18, 2012>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Dec 18, 2012|
|Previous Article:||Siemens awarded contract to supply three more super-efficient gas turbines for US power plant.|
|Next Article:||Autonomy's solutions selected by North Shore Credit Union.|